- Home
- HCTI vs KPRX Comparison
HCTI vs KPRX Comparison
Compare HCTI & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCTI | KPRX |
|---|---|---|
| Founded | 2020 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4M | 11.3M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | HCTI | KPRX |
|---|---|---|
| Price | $0.69 | $2.57 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 11.6K |
| Earning Date | 11-12-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,891,000.00 | N/A |
| Revenue This Year | $179.58 | N/A |
| Revenue Next Year | $4.39 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 18.77 | N/A |
| 52 Week Low | $0.14 | $1.76 |
| 52 Week High | $9.97 | $2.95 |
Technical Indicators
Market Signals| Indicator | HCTI | KPRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.88 | 45.53 |
| Support Level | $0.65 | $2.45 |
| Resistance Level | $1.01 | $2.61 |
| Average True Range (ATR) | 0.23 | 0.09 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 1.79 | 0.00 |
Price Performance
Historical ComparisonAbout HCTI Healthcare Triangle Inc.
Healthcare Triangle Inc is a healthcare information technology company focused on advancing industry-transforming solutions in the sectors of cloud services, data science, and professional and managed services for the healthcare and life sciences industry. The company reinforces healthcare progress through technology and extensive industry know-how. HTI supports healthcare providers and payors, hospitals, and Pharma Life Sciences organizations in their efforts to improve health outcomes by enabling the adoption of new technologies, data enlightenment, business agility, and accelerated response to immediate business needs and competitive threats. It provides services under three operating segments: Software Services, Managed Services, and Support and Corporate & others.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.